Beam Therapeutics Inc

Item 5. Other Information.

(a)

On August 3, 2024, Bethany Cavanagh, our Senior Vice President, Finance, was appointed to the positions of Treasurer and principal accounting officer of the Company, to be effective upon the resignation of Terry-Ann Burrell as our Chief Financial Officer and Treasurer on August 9, 2024.

Ms. Cavanagh, age 49, has served as our Senior Vice President, Finance, since August 2021, and previously served as our Vice President, Finance, beginning in April 2019. Prior to her role with us, Ms. Cavanagh held the position of Executive Director of Financial Planning and Analysis with CRISPR Therapeutics, a gene editing company, beginning in January 2017. Ms. Cavanagh holds a Bachelor's degree in English from Roger Williams University and a Master’s degree in Business Administration from Babson College.

In connection with Ms. Cavanagh’s appointment as Treasurer and principal accounting officer, the compensation committee of our board of directors approved the grant to Ms. Cavanagh of an option to purchase 5,000 shares of our common stock and of 2,500 restricted stock units, with effective grant dates of August 31, 2024 and September 30, 2024, respectively. The option will vest in 48 equal monthly installments, and the restricted stock units will vest in four equal annual installments, in each case subject to Ms. Cavanagh’s continued employment with us through the applicable vesting date.

We and Ms. Cavanagh will also enter into our standard form of indemnification agreement, a copy of which was filed as Exhibit 10.12 to our Registration Statement on Form S-1 (File No. 333- 233985) filed with the Securities and Exchange Commission on September 27, 2019.

(c)

Director and Officer Trading Arrangements

The following table describes for the quarterly period covered by this report each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement,” or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

completed or expire without execution.